Patents Examined by Yong Chu
  • Compounds for alzheimer's disease
    Patent number: 7678823
    Abstract: The invention provides novel compounds useful for the treatment of neurodegenerative disorders including Alzheimer's disease and dementia. The compounds have a substituents chosen from -L-C(?O)OH, -L-CH?CHC(?O)OH, -L-C(?O)NH2, -L-C(?O)NH(C1-3 alkyl), -L-C(?O)N(C1-3 alkyl)2, -L-S(?O)2(C1-3alkyl), -L-S(?O)2NH2, -L-S(?O)2N(C1-3 alkyl)2, -L-S(?O)2NH(C1-3 alkyl), -L-C(?O)NHOH, -L-C(?O)CH2NH2, -L-C(?O)CH2OH, -L-C(?O)CH2SH, -L-C(?O)NHCN, -L-NHC(?O)ORo, -L-C(?O)NHRo, -L-NH(C?O)NHRo, -L-C(?O)N(Ro)2, -L-NH(C?O)N(Ro)2, -L-sulfo, -L-(2,6 difluorophenol), -L-phosphono, and -L-tetrazolyl, where L is a linker.
    Type: Grant
    Filed: April 4, 2007
    Date of Patent: March 16, 2010
    Assignee: Myriad Pharmaceticals, Inc.
    Inventors: Rachel Slade, Yevgeniya Klimova, Robert J. Halter, Ashantai J. Yungai, Warren S. Weiner, Ruth J. Walton, Jon Adam Willardsen, Mark B. Anderson, Kenton Zavitz
  • Substituted aniline derivatives
    Patent number: 7678785
    Abstract: The present invention relates to novel aniline derivatives and their use in therapy, in particular their use in the treatment of fungal infections.
    Type: Grant
    Filed: July 24, 2007
    Date of Patent: March 16, 2010
    Assignee: UCB Pharma S.A.
    Inventors: Andrew David Carr, Judi Charlotte Neuss, Michael Glen Orchard, David William Porter
  • Heteroaryl and benzyl amide compounds
    Patent number: 7674815
    Abstract: Compounds of formula I processes for their preparation, their use as pharmaceuticals and to pharmaceutical compositions comprising them.
    Type: Grant
    Filed: January 29, 2007
    Date of Patent: March 9, 2010
    Assignee: Hoffmann-La Roche Inc.
    Inventors: Christoph Faeh, Holger Kuehne, Thomas Luebbers, Patrizio Mattei, Cyrille Maugeais, Philippe Pflieger
  • Cycloalkylamino acid derivatives
    Patent number: 7671043
    Abstract: The invention relates to compounds of formula I and to pharmaceutically acceptable salts, prodrugs, solvates or hydrates thereof; wherein B, D, E, R1, R2, R3, R4, R5, R8, m, n, p, q, r, s, t and u are as defined herein. This invention also relates to a method of using such compounds in the treatment of hyperproliferative diseases and autoimmune diseases in mammals, especially humans, and to pharmaceutical compositions containing such compounds.
    Type: Grant
    Filed: May 9, 2007
    Date of Patent: March 2, 2010
    Assignee: Pfizer Inc
    Inventor: Robert John Maguire
  • Thiazolidinone amides, thiazolidine carboxylic acid amides, and serine amides, including polyamine conjugates thereof, as selective anti-cancer agents
    Patent number: 7662842
    Abstract: Substituted thiazolidinone carboxylic acid amides and substituted thiazolidine carboxylic acid amides according to formulae (I) and (II) are disclosed where the various substituent groups are as defined in the specification. Methods of making these compounds, pharmaceutical compositions containing the compounds, and their use, particularly for treating or preventing cancer, are also disclosed.
    Type: Grant
    Filed: July 19, 2006
    Date of Patent: February 16, 2010
    Assignees: Ohio State Univesity Research Foundation, The University of Tennessee Research Foundation
    Inventors: Duane D. Miller, James T. Dalton, Veeresa Gududuru, Eunju Hurh
  • Diaryl ether ?adrenergic receptor agonists
    Patent number: 7662815
    Abstract: The invention provides novel ?2 adrenergic receptor agonist compounds. The invention also provides pharmaceutical compositions comprising such compounds, methods of using such compounds to treat diseases associated with ?2 adrenergic receptor activity, and processes and intermediates useful for preparing such compounds.
    Type: Grant
    Filed: November 19, 2007
    Date of Patent: February 16, 2010
    Assignee: Theravance, Inc.
    Inventors: Robert Murray McKinnell, Edmund J. Moran
  • HIF hydroxylase inhibitors
    Patent number: 7662854
    Abstract: The invention provides a compound of one of the formulae (A), (B), (C), (D), (E), (F) as herein defined, or a salt thereof, for use in the treatment of a condition associated with increased or decreased HIF levels or activity, or a condition in which an increase or decrease in HIF levels or activity may be beneficial.
    Type: Grant
    Filed: September 11, 2006
    Date of Patent: February 16, 2010
    Assignee: ISIS Innovation Limited
    Inventors: Christopher Joseph Schofield, Patrick Henry Maxwell, Christopher William Pugh, Peter John Ratcliffe
  • Triazole compounds that modulate HSP90 activity
    Patent number: 7662813
    Abstract: The present invention relates to substituted triazole compounds and compositions comprising substituted triazole compounds. The invention further relates to methods of inhibiting the activity of Hsp90 in a subject in need thereof and methods for preventing or treating hyperproliferative disorders, such as cancer, in a subject in need thereof comprising administering to the subject a substituted triazole compound of the invention, or a composition comprising such a compound.
    Type: Grant
    Filed: August 17, 2006
    Date of Patent: February 16, 2010
    Assignee: Synta Pharmaceuticals Corp.
    Inventors: Weiwen Ying, David James, Shijie Zhang, Teresa Przewloka, Elena Kostik, Junghyun Chae, Howard P Ng, Zhenjian Du, James Barsoum, Dinesh Chimmanamada, Chi-Wan Lee, Kevin Foley
  • Acylhydrazones as kinase modulators
    Patent number: 7662824
    Abstract: The invention is directed to acylhydrazones compounds of Formula I: where R1, R2 and A are as defined herein, the use of such compounds as protein tyrosine kinase modulators, particularly inhibitors of c-Met, and the use of such compounds to reduce or inhibit kinase activity of c-Met in a cell or a subject, and modulate c-Met expression in a cell or subject, and the use of such compounds for preventing or treating in a subject a cell proliferative disorder and/or disorders related to c-Met. The present invention is further directed to pharmaceutical compositions comprising the compounds of the present invention and to methods for treating conditions such as cancers and other cell proliferative disorders.
    Type: Grant
    Filed: March 16, 2006
    Date of Patent: February 16, 2010
    Assignee: Janssen Pharmaceutica NV
    Inventors: Kristi Leonard, Tianbao Lu, Robert W. Tuman, Dana L. Johnson, Anna C. Maroney, Jan L. Sechler, Richard W. Connors, Richard S. Alexander, Maxwell D. Cummings, Robert A. Galemmo, Thomas P. Markotan
  • Hepatitis C virus inhibitors
    Patent number: 7659270
    Abstract: The present disclosure relates to compounds, compositions and methods for the treatment of hepatitis C virus (HCV) infection. Also disclosed are pharmaceutical compositions containing such compounds and methods for using these compounds in the treatment of HCV infection.
    Type: Grant
    Filed: August 8, 2007
    Date of Patent: February 9, 2010
    Assignee: Bristol-Myers Squibb Company
    Inventors: Carol Bachand, Makonen Belema, Daniel H. Deon, Andrew C. Good, Jason Goodrich, Clint A. James, Rico Lavoie, Omar D. Lopez, Alain Martel, Nicholas A. Meanwell, Van N. Nguyen, Jeffrey Lee Romine, Edward H. Ruediger, Lawrence B. Snyder, Denis R. St. Laurent, Fukang Yang, David R. Langley, Lawrence G. Hamann
  • Heterocyclic CETP inhibitors
    Patent number: 7652023
    Abstract: Compounds of formula Ia and Ib wherein A, B, C and R1 are described herein.
    Type: Grant
    Filed: November 16, 2006
    Date of Patent: January 26, 2010
    Assignee: Bristol-Myers Squibb Company
    Inventors: Yufeng Wang, Wu Yang
  • Tetramerous derivative of indole-3-carbinol with anti-carcinogenic activity and method of synthesis of said derivative
    Patent number: 7645788
    Abstract: Use of the tetramerous derivative of indole-3-carbinol having formula I for preparing a medicinal having anti-carcinogenic activity, and method of synthesis of the tetramerous derivative having formula I, in which indole-3-carbinol is reacted with an oxidizing agent so as to cause a polymeric oxidation of indole-3-carbinol.
    Type: Grant
    Filed: June 5, 2002
    Date of Patent: January 12, 2010
    Assignee: Universita' Degli Studi Di Urbino
    Inventors: Mauro Magnani, Chiara Fiorucci, Paolino Filippone, Giorgio Brandi, Mirko Paiardini
  • Process for preparing duloxetine and intermediates for use therein
    Patent number: 7645890
    Abstract: A process for preparing (+)duloxetine, or an acid addition salt thereof, which process comprises resolving racemic(±)duloxetine with a chiral acid so as to obtain a salt of the chiral acid and (+)duloxetine, substantially free of (?)duloxetine; and (ii) if desired, converting the salt prepared in step (i) to the free base or another acid addition salt as appropriate. The process for preparing (+)duloxetine, or an acid addition salt thereof, can further comprise an O-alkylation intermediate process step which is carried out in the presence of a base and a phase transfer catalyst.
    Type: Grant
    Filed: December 10, 2003
    Date of Patent: January 12, 2010
    Assignee: Cipla Limited
    Inventors: Dharmaraj Ramachandra Rao, Rajendra Narayanrao Kankan
  • Sulfonyl substituted 1H-indoles as ligands for the 5-hydroxytryptamine receptors
    Patent number: 7645752
    Abstract: The present invention is directed to compounds of Formula I: which are modulators of the 5-hydroxtryptamine-6 and 5-hydroxytryptamine-2A receptors and which are inhibitors of norepinephrine reuptake. The compounds of the invention, and pharmaceutical composition thereof, are useful in the treatment of disorders related to or associated with the 5-hydroxytryptamine-6 and 5-hydroxtryptamine-2A receptors or with norepinephrine reuptake inhibition.
    Type: Grant
    Filed: January 12, 2007
    Date of Patent: January 12, 2010
    Assignee: Wyeth LLC
    Inventors: Robert E. McDevitt, Yanfang Li, Albert J. Robichaud, Gavin D. Heffernan, Richard D. Coghlan, Ronald C. Bernotas
  • Histone deacetylase inhibitors
    Patent number: 7642275
    Abstract: Compounds, pharmaceutical compositions, kits and methods are provided for use with histone deacetylases (HDACs) that comprise a compound of the formulae: wherein the variables are as defined herein.
    Type: Grant
    Filed: December 16, 2005
    Date of Patent: January 5, 2010
    Assignee: Takeda San Diego, Inc.
    Inventors: Jerome C. Bressi, Jason W. Brown, Robert J. Skene, Jeffrey A. Stafford, Phong H. Vu, Anthony R. Gangloff, Andrew J. Jennings, Stephen W. Kaldor
  • Compounds for use in the treatment of autoimmune diseases, immuno-allergical diseases and organ or tissue transplantation rejection
    Patent number: 7642290
    Abstract: The present invention provides compounds, pharmaceutical compositions and methods for treating, immuno-allergical diseases, autoimmune diseases, and organ or tissue rejection following transplantation.
    Type: Grant
    Filed: October 1, 2003
    Date of Patent: January 5, 2010
    Assignee: Novaremed Limited
    Inventor: Eliahu Kaplan
  • Fused heteroaryl derivatives for use as P38 kinase inhibitors
    Patent number: 7642276
    Abstract: Compounds of formula (I): wherein A is a 5-membered heteroaryl ring are inhibitors of p38 kinase and are useful in the treatment of conditions or disease states mediated by p38 kinase activity or mediated by cytokines produced by the activity of p38, such as rheumatoid arthritis.
    Type: Grant
    Filed: July 30, 2003
    Date of Patent: January 5, 2010
    Assignee: SmithKline Beecham Corporation
    Inventors: Richard Martyn Angell, Ian Robert Baldwin, Paul Bamborough, Nigel Marc Deboeck, Timothy Longstaff, Stephen Swanson
  • Compounds having selective cytochrome P450RAI-1 or selective cytochrome P450RAI-2 inhibitory activity and methods of obtaining the same
    Patent number: 7638648
    Abstract: Compounds of formulas 1 through 17 provided in the specification specifically or selectively inhibit either the cytochrome P450RAI-1 enzyme or the cytochrome P450RAI-2 enzyme.
    Type: Grant
    Filed: March 23, 2007
    Date of Patent: December 29, 2009
    Assignee: Allergan Inc.
    Inventors: Jayasree Vasudevan, Liming Wang, Xiaoxia Liu, Kwok Yin Tsang, Ling Li, Janet A. Takeuchi, Thong Vu, Richard Beard, Smita Bhat, Vidyasagar Vuligonda, Roshantha A. Chandraratna
  • 1, 3, 4-oxadiazol-2-ones as peroxisome-proliferator activated receptor delta modulators and their use in the treatment of neurological and metabolic disease
    Patent number: 7638539
    Abstract: The present invention is directed to 1,3,4-oxadiazalones, i.e., the compounds of formula I and their pharmaceutically acceptable salts, stereoisomers, tautomers, or solvates thereof. Novel compounds include those of formula I, in which radicals are as defined herein. The compounds of this invention are modulators of PPARdelta and therefore useful as pharmaceutical agents, especially for the treatment of demyelinating diseases and disorders of fatty acid metabolism and glucose utilization such as multiple scleroses.
    Type: Grant
    Filed: September 27, 2006
    Date of Patent: December 29, 2009
    Assignees: Aventis Pharmaceuticals Inc., Sanofi-Aventis Deutschland GmbH
    Inventors: Daniel G. McGarry, Jochen Goerlitzer, Stefanie Keil, Karen Chandross, Jean Merrill, Wolfgang Wendler
  • Mitotic kinesin inhibitors
    Patent number: 7638549
    Abstract: The present invention relates to dihydropyrrole compounds that are useful for treating cellular proliferative diseases, for treating disorders associated with KSP kinesin activity, and for inhibiting KSP kinesin. The invention is also related to compositions which comprise these compounds, and methods of using them to treat cancer in mammals.
    Type: Grant
    Filed: August 11, 2004
    Date of Patent: December 29, 2009
    Assignee: Merck & Co. Inc.
    Inventors: Paul J. Coleman, Christopher D. Cox